Canaccord Genuity reissued their buy rating on shares of NuVasive (NASDAQ: NUVA) in a research report released on Wednesday morning. Canaccord Genuity currently has a $25.00 price target on the stock, up from their previous price target of $22.50.
“We note strength across all key business units in Q4/12 including XLIF, both US and OUS, and biologics is encouraging, capping off a lumpy 2012. Additionally, 2013 appears to be a year of major initiatives as the company anticipates major growth in Japan as well as multiple new product launches into the US markets.,” Canaccord Genuity’s analyst commented.
NUVA has been the subject of a number of other recent research reports. Analysts at Piper Jaffray raised their price target on shares of NuVasive to $24.00 in a research note to investors on Wednesday. Separately, analysts at BMO Capital Markets reiterated a market perform rating on shares of NuVasive in a research note to investors on Wednesday. They now have a $18.00 price target on the stock, up previously from $17.00. Finally, analysts at RBC Capital raised their price target on shares of NuVasive from $18.00 to $21.00 in a research note to investors on Wednesday. They now have a sector perform rating on the stock.
NuVasive opened at 18.35 on Wednesday. NuVasive has a 1-year low of $12.35 and a 1-year high of $25.99. The stock’s 50-day moving average is currently $17.50. The company has a market cap of $800.6 million and a price-to-earnings ratio of 265.29.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
